
Clene Inc.
NASDAQ:CLNN
6.39 (USD) • At close September 2, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Clene Inc. |
Symbool | CLNN |
Munteenheid | USD |
Prijs | 6.39 |
Beurswaarde | 53,751,172 |
Dividendpercentage | 0% |
52-weken bereik | 2.28 - 6.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Robert Etherington MBA |
Website | https://clene.com |
An error occurred while fetching data.
Over Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)